Orgalutran solution for s/c injection

国家: 亚美尼亚

语言: 英文

来源: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

有效成分:

ganirelix (ganirelix acetate)

可用日期:

N.V. Organon

ATC代码:

H01CC01

INN（国际名称）:

ganirelix (ganirelix acetate)

剂量:

0,25mg/0,5ml

药物剂型:

solution for s/c injection

每包单位数:

(5) pre-filled syringes 0,5ml

处方类型:

Prescription

授权状态:

Registered

授权日期:

2021-05-21

产品特点

1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Orgalutran 0.25 mg/0.5 mL solution for injection
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each pre-filled syringe contains:
Active ingredient: ganirelix acetate 0.25 mg in 0.5 ml aqueous
solution.
Excipients: mannitol, glacial acetic acid 99%, sodium hydroxide and/or
glacial acetic acid, water for
injections.
Excipient with known effect:
This medicinal product contains less than 1 mmol sodium (23 mg) per
injection, i.e. essentially
‘sodium-free’.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Solution for injection.
Clear and colorless aqueous solution.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
The prevention of premature luteinizing hormone (LH) surges in women
undergoing controlled ovarian
hypestimulation (COH) for assisted reproduction techniques (ART).
In clinical trials Orgalutran was used with recombinant follicle
stimulating hormone (FSH) or corifollitropin
alfa, the sustained follicle stimulant.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Orgalutran should only be prescribed by a specialist experienced in
the treatment of infertility.
Posology
Orgalutran is used to prevent premature LH surges in patients
undergoing COH. Controlled ovarian
hyperstimulation with FSH or corifollitropin alfa may start at day 2
or 3 of menses. Orgalutran (0.25 mg)
should be injected subcutaneously once daily, starting in general on
day 5 or day 6 of FSH administration or on
day 5 or day 6 following the administration of corifollitropin alfa.
In high responders an early LH rise may be
prevented by starting Orgalutran treatment on day 5. The start of
Orgalutran may be delayed in absence of
follicular growth.
Orgalutran and FSH should be administered approximately at the same
time. However, the preparations should
not be mixed and different injection sites are to be used.
FSH dose adjustments should be based on the number and size of growing
follicles, rather than on the amount
of circulating oestradiol. (see S